null Lorenzo Ferri, MD, PhD

Senior Scientist, RI-MUHC, Montreal General Hospital site

Cancer Research Program

Centre for Translational Biology

Professor, Department of Surgery, Faculty of Medicine and Health Sciences, McGill University

Department of Surgery, Division of Adult Thoracic Surgery, MUHC



gastroesophageal cancer • therapy resistance • cancer models • translational research

Research Focus

My research focuses on improving outcomes in the treatment of gastric and esophageal cancers, as well as on the basic mechanisms involved in resistance to neoadjuvant/adjuvant therapy and the development of model systems/tumour avatars to investigate and identify clinically useful approaches to abrogate such resistance. I also have a strong research interest in the role of the microenvironment in cancer progression and resistance to therapy, specifically focusing on the role played by inflammation, bacterial antigens and host neutrophils in these processes. My team is involved with several large team projects, including studies funded by the Cancer Research UK Grand Challenge and Marathon of Hope mechanisms; I am also the lead investigator for Department of Defense (Impact) and Canadian Cancer Society/CIHR (Breakthrough) group grants that aim to translate high-throughput patient-specific cancer model-based drug testing approaches into clinical applications.

Selected Publications

Click on Pubmed to see my current publications list

  • Evaristo G, Katz A, Ramírez-GarcíaLuna JL, Issac MSM, Sangwan V, Thai DV, Bertos N, Guiot MC, Camilleri-Broët S, Marcus V, Mueller C, Cools-Lartigue J, Fiset PO, Ferri LE. Relation between mismatch repair status, chemoresponse, survival and anatomic location in gastroesophageal adenocarcinoma. Can J Surg. 2023 Feb 15;66(1):E79-E87. doi: 10.1503/cjs.017021. PMID: 36792128.

  • Sangwan V, Al-Marzouki L, Pal S, Stavrakos V, Alzahrani M, Antonatos D, Nevo Y, Camilleri-Broët S, Rayes R, Bourdeau F, Giannias B, Bertos N, Bailey S, Rousseau S, Cools-Lartigue J, Spicer JD, Ferri L. Inhibition of LPS-mediated TLR4 activation abrogates gastric adenocarcinoma-associated peritoneal metastasis. Clin Exp Metastasis. 2022 Apr;39(2):323-333. doi: 10.1007/s10585-021-10133-8. Epub 2021 Nov 12. PMID: 34767138.

  • Al Lawati Y, Cools-Lartigue J, Ramirez-GarciaLuna JL, Molina-Franjola JC, Pham D, Skothos E, Mueller C, Spicer J, Ferri L. Dynamic Alteration of Neutrophil-to-Lymphocyte Ratio over Treatment Trajectory is Associated with Survival in Esophageal Adenocarcinoma. Ann Surg Oncol. 2020 Oct;27(11):4413-4419. doi: 10.1245/s10434-020-08521-7. Epub 2020 May 3. PMID: 32363513.

  • Rayes RF, Vourtzoumis P, Bou Rjeily M, Seth R, Bourdeau F, Giannias B, Berube J, Huang YH, Rousseau S, Camilleri-Broet S, Blumberg RS, Beauchemin N, Najmeh S, Cools-Lartigue J, Spicer JD, Ferri LE. Neutrophil Extracellular Trap- Associated CEACAM1 as a Putative Therapeutic Target to Prevent Metastatic Progression of Colon Carcinoma. J Immunol. 2020 Apr 15;204(8):2285-2294. doi: 10.4049/jimmunol.1900240. Epub 2020 Mar 13. PMID: 32169849.

  • Sudarshan M, Alcindor T, Ades S, Aloraini A, van Huyse M, Asselah J, David M, Frechette D, Brisson S, Thirlwell M, Ferri L. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. Ann Surg Oncol. 2015 Jan;22(1):324-30. doi: 10.1245/s10434-014-3875-3. Epub 2014 Jul 15. PMID: 25023544.